MedTrace Logo

Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora

NCT01192802 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2013-01-24

No results posted yet for this study

Summary

Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy in the school children population. The aim of this study is to evaluate the efficacy of the albendazole one versus two and three doses, in school children infected with intestinal helminth.

Conditions

  • Intestinal Diseases
  • Helminthiasis

Interventions

DRUG

albendazole

1 tablet of 400 mg of albendazole per day for three consecutive days

DRUG

albendazole

single 1 tablet of 400 mg of albendazole

DRUG

albendazole

1 tablet of 400 mg of albendazole per day for two consecutive days

Sponsors & Collaborators

  • Albert Schweitzer Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Gabon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01192802 on ClinicalTrials.gov